Phase 1 umbrella trial for hematologic malignancies open for enrollment
Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Phase 1 umbrella trial for hematologic malignancies open for enrollment
Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| TCRX | 0.9310 | +0.0024 | +0.26% |
| Tscan Therapeutics Inc | |||